The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation

International Journal of Geriatric Psychiatry

Volumn 23, Issue 1, 2008, Pages 116-117

  Passmore, Michael J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR AGONIST; CITALOPRAM; DONEPEZIL; GABAPENTIN; LORAZEPAM; MEMANTINE; NABILONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; TRAZODONE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEDTIME DOSAGE; BEHAVIOR DISORDER; CASE REPORT; COGNITIVE DEFECT; DISEASE COURSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LABORATORY TEST; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT TRANSPORT; RESTLESSNESS; UNSPECIFIED SIDE EFFECT;

AGED; ALZHEIMER DISEASE; ANTI-ANXIETY AGENTS; HUMANS; MALE; PSYCHOMOTOR AGITATION; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 38749148061     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1828     Document Type: Article

References (5)

1. Eubanks LM, Rogers CJ, Iv AE, et al. 2006. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 3(6): 773-777.
2. Pazos MR, Nunez E, Benito C, et al. 2004. Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life Sci 75(16): 1907-1915.
3. Ramirez BG, Blazquez C, Gomez del Pulgar T, et al. 2005. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25(8): 1904-1913.
4. Volicer L, Stelly M, Morris J, et al. 1997. Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12(9): 913-919.
5. Walther S, Mahlberg R, Eichmann U, Kunz D. 2006. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 185(4): 524-528.